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Prognostic Value of Midregional Pro-Adrenomedullin
in Patients With Acute Myocardial Infarction
The LAMP (Leicester Acute Myocardial Infarction Peptide) Study
Sohail Q. Khan, BSC (HONS), MBCHB, MRCP,* Russell J. O’Brien, MBCHB, MRCP,*
Joachim Struck, PHD,† Paulene Quinn, MPHIL,* Nils Morgenthaler, PHD,† Iain Squire, MD, FRCP,*
Joan Davies, PHD, FRCP,* Andreas Bergmann, PHD,† Leong L. Ng, MD, FRCP*
Leicester, United Kingdom; and Hennigsdorf, Germany
Objectives This study sought to assess the prognostic impact of midregional pro-adrenomedullin (MR-proADM) after an
acute myocardial infarction (AMI).
Background Adrenomedullin (ADM) is elevated in heart failure (HF) and after AMI. Another part of its precursor, MR-proADM,
is more stable in circulation and ex vivo. We investigated the cardiovascular prognostic value after AMI of MR-
proADM and compared it with N-terminal pro-B-type natriuretic peptide (NTproBNP), a marker of death and HF.
Methods We measured plasma MR-proADM and NTproBNP in 983 consecutive post-AMI patients (721 men, mean age
65.0  12.2 years), 3 to 5 days after chest pain onset.
Results There were 101 deaths and 49 readmissions with HF during follow-up (median 342, range 0 to 764 days). The
MR-proADM was increased in patients with death or HF compared with survivors (median 1.19 nmol/l, range
0.09 to 5.39 nmol/l, vs. 0.71 nmol/l, range 0.25 to 6.66 nmol/l, p  0.0001). Using a multivariate binary logis-
tic model, log MR-proADM (odds ratio 4.22) and log NTproBNP (odds ratio 3.20) were significant independent
predictors of death or HF (with creatinine, age, gender, and history of AMI). The areas under the receiver-
operating characteristic curve for MR-proADM, NTproBNP, and the logistic model with both markers were 0.77,
0.79, and 0.84 respectively. Cox models for the predictors of death or HF showed the same variables (including
log MR-proADM, hazard ratio 3.63; log NTproBNP, hazard ratio 2.67). The MR-proADM provided further risk strat-
ification in those patients who had NTproBNP levels above the median (p  0.0001). Findings were similar for
death and HF as individual end points.
Conclusions The ADM system is activated after AMI. The MR-proADM is a powerful predictor of adverse outcome, especially
in those with an elevated NTproBNP. The MR-proADM may represent a clinically useful marker of prognosis after
AMI. (J Am Coll Cardiol 2007;49:1525–32) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.12.038a
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ihe identification of patients at high risk of adverse
utcome after acute myocardial infarction (AMI) remains a
hallenge. Circulating natriuretic peptide levels such as
-terminal pro-B-type natriuretic peptide (NTproBNP)
rovide prognostic information regarding the risk of death
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006, accepted December 5, 2006.nd heart failure after AMI (1). The prognostic superiority
f these biomarkers compared with consideration of clinical
eatures has been borne out in a range of acute coronary
yndromes (2). Newer peptides are emerging that may give
omplementary and additional information, particularly in a
ultimarker strategy with NTproBNP. Adrenomedullin
ADM) is a 52-amino-acid peptide that has homology with
alcitonin gene-related peptide (3). This peptide was orig-
nally isolated from human pheochromocytoma cells by a
roup of Japanese scientists who were screening these cells
y looking for peptides that increased cyclic adenosine
onophosphate (cAMP) levels in platelets. Adrenomedul-
in has subsequently been detected in other tissues, includ-
ng adrenal medulla, heart, brain, lung, kidney, and gastro-
ntestinal organs (3,4), and its mRNA is highly expressed in
ndothelial cells (5). The downstream actions of ADM are
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Pro-Adrenomedullin in AMI April 10, 2007:1525–32mediated by an increase in
cAMP levels (6), causing potent
vasodilatation and hypotension
(7), and ADM may also have
autocrine or paracrine actions.
Adrenomedullin is synthesized
as part of a larger precursor
molecule, termed preproad-
renomedullin. In humans this
precursor consists of 185 amino
acids (8). The gene encoding
preproadrenomedullin is termed
the ADM gene and has been
mapped and localized to chro-
mosome 11 (9). Adrenomedullin
is difficult to measure in plasma
because it is partially complexed
with complement factor H and
s rapidly cleared from the circulation (10). Recently, the
ore stable midregional fragment of pro-ADM (MR-
roADM), comprising amino acids 45 to 92 of pre-
roADM, has been identified, and is more stable than the
ctive molecule being secreted in equimolar amounts to
DM (11).
The biological activity of ADM in the cardiovascular
ystem is similar to that of B-type natriuretic peptide (BNP)
ausing vasodilation (12) via production of nitric oxide (13),
ncreasing cardiac output (14), and inducing diuresis and
atriuresis (15). Plasma ADM is increased in heart failure in
roportion to the severity of disease (16,17) and is inversely
elated to left ventricular ejection fraction.
Plasma ADM has been investigated previously in 2 small
tudies as a prognostic marker comparing it with NT-
roBNP and BNP (1,18). One study identified plasma
DM as an independent predictor of cardiogenic shock and
hort-term mortality (18), whereas ADM had no indepen-
ent additional prognostic value to NTproBNP in another
1). The potential role of the more stable prohormone
R-proADM in prognostication after AMI is unknown.
n this study we investigated whether MR-proADM would
e of benefit in determining the prognosis after AMI,
articularly for predicting death and heart failure. We
ompared this with NTproBNP, a peptide of established
rognostic value in this group of patients (1,19,20).
ethods
tudy population. We studied 983 consecutive acute myo-
ardial infarction patients admitted to the Coronary Care
nit of Leicester Royal Infirmary. The study complied with
he Declaration of Helsinki and was approved by the local
thics committee; written informed consent was obtained
rom patients. Acute myocardial infarction was defined at
resentation with at least 2 of 3 standard criteria (i.e.,
ppropriate symptoms, acute electrocardiographic changes
Abbreviations
and Acronyms
ADM  adrenomedullin
AMI  acute myocardial
infarction
HF  heart failure
MR-proADM  midregional
pro-adrenomedullin
NSTEMI  non–ST-segment
elevation myocardial
infarction
NTproBNP  N-terminal
pro-B-type natriuretic
peptide
STEMI  ST-segment
elevation myocardial
infarctionf infarction [ST-segment elevation or depression, new left pundle branch block], and an increase in troponin T above
he 99th percentile for our population). Acute myocardial
nfarction was subcategorized into ST-segment elevation
yocardial infarction (STEMI) or non–ST-segment eleva-
ion myocardial infarction (NSTEMI). Exclusion criteria
ere known malignancy or surgery in the previous month.
lasma samples. Blood samples were drawn at 3 to 5 days
fter the onset of chest pain for determination of plasma
R-proADM and NTproBNP. After 15 min of bed rest,
0 ml of blood was collected into tubes containing ethyl-
nediaminetetraacetic acid and aprotinin. All plasma was
tored at 70°C until assayed in a blinded fashion in a
ingle batch.
TproBNP assay. Our NTproBNP assay was based on a
oncompetitive assay as previously published (2). Sheep
ntibodies were raised to the N-terminal of human NT-
roBNP, and monoclonal mouse antibodies were raised to
he C-terminal. The N-terminal immunoglobulin G was
ffinity-purified and biotinylated. Samples or NTproBNP
tandards were incubated in C-terminal immunoglobulin
–coated wells with the biotinylated N-terminal antibody
or 24 h at 4°C. Detection was with methyl-acridinium
ster–labeled streptavidin on an MLX plate luminometer
Dynex Technologies Ltd., Worthing, United Kingdom).
he lower limit of detection was 0.3 pmol/l. There was no
ross-reactivity with atrial natriuretic peptide, BNP, or
-type natriuretic peptide.
R-proADM assay. The MR-proADM was detected us-
ng a novel commercial assay in the chemiluminescence/coated
ube format (BRAHMS AG, Hennigsdorf, Germany) as
reviously described (21). Briefly, tubes were coated with a
urified sheep polyclonal antibody raised against a peptide
epresenting amino acids 83 to 94 of preproADM (Fig. 1).
purified sheep polyclonal antibody raised against a pep-
ide representing amino acids 68 to 86 of preproADM was
abeled with methylacridinium N-hydroxysuccinimide ester
InVent GmbH, Hennigsdorf, Germany) and used as a
racer. Dilutions of a peptide representing amino acids 45 to
2 of preproADM in normal horse serum served as stan-
ards. The immunoassay was performed by incubating
0-l samples/standards and 200-l tracer in coated tubes
or 2 h at room temperature. Tubes were washed 4 times
ith 1-ml immunoassay wash solution (BRAHMS AG),
nd bound chemiluminescence was measured using an
B952T luminometer (Berthold, Bad Wildbad, Germany).
he MR-proADM assay has been characterized in detail
reviously (21). The lower detection limit of the assay is
.08 nmol/l; the functional assay sensitivity (defined as the
owest concentration detectable with an interassay coeffi-
ient of variation [CV] of 20%) is 0.12 nmol/l. The
ntra-assay CV at 0.5 and 5 nmol/l is 3% and 3.5%,
espectively; the interassay CV at 0.5 and 5 nmol/l is 8.5%
nd 6.5%, respectively.
nd points. We assessed the value of both MR-proADM
nd NTproBNP for the prediction of the combined
rimary end point of death and heart failure and for death
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April 10, 2007:1525–32 Pro-Adrenomedullin in AMIr heart failure as individual secondary end points.
ospitalization for heart failure was defined as a hospital
dmission for which heart failure was the primary reason.
nd points were obtained by reviewing the Office of
ational Statistics Registry and by contacting each pa-
ient. There was a minimum 30-day follow-up of all
urviving patients.
tatistical analysis. Statistical analyses were performed
sing SPSS version 12 (SPSS Inc., Chicago, Illinois). The
ontinuous variables in the 2 independent groups were
ompared using the Mann-Whitney U test. To test the
ndependent predictive power for death or heart failure of
eptides levels above and below the median, binary logistic
egression analyses were conducted. We included as vari-
bles baseline patient characteristics (age, gender, serum
reatinine, Killip class, and territory of AMI) and peptide
arkers (including troponin I). Levels of NTproBNP and
R-proADM were normalized by log transformation.
hus, odds ratios and hazard ratios refer to a 10-fold
ncrease in the levels of these markers. Spearman correla-
ions were performed for peptide values and continuous
ariables. To compare the predictive value of NTproBNP,
R-proADM, or the predicted probability derived from
ogistic regression analyses, receiver-operating characteristic
urves were generated and the area under the curve (AUC)
as calculated. To identify the independent predictors of
eath or heart failure, Cox proportional hazard analyses
ere used. Kaplan-Meier survival curves were generated to
isualize the relationship between the peptides NTproBNP
nd MR-proADM, and the primary and secondary end
oints and Mantel-Cox log rank tests (22) were used to
ssess the significance of the stratification using medians of
R-proADM (and log rank tests for linear trend of factor
evels for stratification using ordered quartiles of MR-
roADM), dichotomized according to NTproBNP median
Figure 1 Principle of the MR-proADM Assay
A sketch of the adrenomedullin (ADM) precursor is shown, and amino acid positi
Tracer- and solid phase–antibodies used in the sandwich immunoassay for the de
adrenomedullin N-terminal 20 peptide; signal  signal peptide.evels. A 2-sided p value of 0.05 was deemed to be itatistically significant. All investigators had full access to
he data and take responsibility for its integrity and accuracy
f the analysis. All investigators have read and agreed to the
rticle as written.
esults
atient characteristics. The demographic features of the
atient population are shown in Table 1. No patient was lost
o follow-up, which ranged from 0 to 764 days with a
edian of 342 days. During follow-up, 101 (10.3%) patients
ied and 49 (5.0%) were readmitted with heart failure. In
84 patients, the AMI was a STEMI event.
R-proADM levels in patients. Plasma levels of MR-
roADM in patients with AMI ranged from 0.09 to 6.66
mol/l with a median of 0.73 nmol/l, being elevated
ompared with the established normal range (mean 0.33
mol/l, range 0.10 to 0.64 nmol/l) (21). The MR-proADM
as higher in patients who died (p  0.0001) or were
eadmitted with heart failure (p  0.0001) compared with
vent-free survivors. Levels were higher in women com-
ared with men (p  0.0001), in patients with a history of
MI (p  0.0001) or hypertension (p  0.0001), and in
atients with a history of heart failure (p  0.001). The
R-proADM levels were not significantly different be-
ween STEMI and NSTEMI patients. The MR-proADM
as lower in patients who received thrombolytic therapy
p  0.043) (Table 2).
The MR-proADM correlated with age (rs  0.552, p 
.0001), log creatinine (rs 0.404, p 0.0001), Killip class
rs  0.314, p  0.0001), and NTproBNP (rs  0.519, p 
.0001).
TproBNP levels in patients. The NTproBNP was
igher in patients who died (p  0.0001) or were readmit-
ed with heart failure (p  0.0001). Significant differences
preproADM are denoted at which the precursor is proteolytically processed.
of midregional pro-adrenomedullin (MR-proADM) are indicated. PAMP  pro-ons in
tectionn NTproBNP levels were noted between men and women
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Pro-Adrenomedullin in AMI April 10, 2007:1525–32p 0.0001), and those with a Killip class1 (p 0.0001)
nd in patients with a history of heart failure (p  0.001) or
MI (p  0.03) (Table 2).
rimary end points: MR-proADM and NTproBNP as
redictors of death and heart failure. The MR-proADM
as increased in patients with death or heart failure com-
ared with survivors (median 1.19 nmol/l, range 0.09 to
.39 nmol/l, vs. median 0.71 nmol/l, range 0.25 to 6.66
mol/l; p  0.0001).
When clinical and demographic characteristics (age, gen-
er, history of AMI, Killip class, log creatinine, NT-
roBNP, and MR-proADM) were entered into a multivar-
ate binary logistic model, MR-proADM (odds ratio [OR]
.22, 95% confidence interval [CI] 1.25 to 14.26, p  0.02)
nd NTproBNP (OR 3.20, 95% CI 2.07 to 4.94, p 
haracteristics of the 983 Patients in the Study Separated by MRp
Table 1 Characteristics of the 983 Patients in the Study Separ
1st Quartile 2nd Quar
Age (yrs) 55.5 10.7 63.5 1
Medical history
AMI 25 (10.2) 37 (15.
Angina pectoris 52 (21.1) 57 (23.
Hypertension 80 (32.5) 105 (42.
Diabetes mellitus 31 (12.6) 53 (21.
High cholesterol 51 (20.7) 56 (22.
Current/ex-smokers 166 (67.5) 153 (62.
ST-segment elevation AMI 187 (76.0) 200 (81.
Thrombolytic 136 (55.3) 131 (53.
Territory of infarct
Anterior 108 (43.9) 106 (43.
Inferior 100 (40.7) 86 (35.
Other 37 (15.1) 54 (22.
Killip class on admission
I 165 (67.0) 134 (54.
II 63 (25.6) 94 (38.
III 10 (4.1) 9 (3.7
IV 1 (0.4) 0 (0)
Peak CK (IU/l) 955.1 1,054.6 1,041.9 1
Creatinine (mol/l) 91.0 17.6 91.3 1
NTproBNP (pmol/l) 1,004.2 2,168.6 1,344.8 1
Male 211 (85.8) 178 (72.
alues are mean (SD) or n (%).
AMI  acute myocardial infarction; CK  creatine kinase; MR-proADM  midregional pro-adren
Comparison of MR-proADM and NTproBNP Level
Table 2 Comparison of MR-proADM and NTp
Median MR-pro
(nmol/l)
Death vs. survivors 1.31 vs. 0.7
Admission with HF vs. no HF 1.10 vs. 0.7
Men vs. women 0.88 vs. 0.7
Previous AMI vs. no AMI 0.88 vs. 0.7
Hypertension vs. normotensives 0.79 vs. 0.7
Previous HF vs. no HF 1.10 vs. 0.7
STEMI vs. NSTEMI 0.73 vs. 0.7
Killip class above I vs. Killip class I 0.84 vs. 0.6HF  heart failure; NSTEMI  non–ST-segment myocardial infarction; STEMI 
in Table 1..0001) independently predicted the primary end point
long with age (OR 1.04), gender (OR for men vs. women
.65), history of AMI (OR 2.51), and log creatinine (OR
.25). The Nagelkerke r2 was 0.35, suggesting a good fit of
he model. Killip class was no longer an independent
redictor of death and heart failure. The receiver-operating
haracteristic curve for MR-proADM yielded an AUC of
.77 (95% CI 0.72 to 0.81, p  0.001); for NTproBNP the
UC was 0.79 (95% CI 0.75 to 0.84, p  0.001). The
redicted probability from the binary logistic model com-
ining the 2 markers yielded an AUC of 0.84 (95% CI 0.81
o 0.88, p  0.001), which exceeded that of either peptide
lone (Fig. 2). Cox proportional hazards modeling con-
rmed that the same variables (namely MR-proADM,
TproBNP, age, gender, history of AMI, and log creati-
M Quartiles
by MRproADM Quartiles
3rd Quartile 4th Quartile p Value
67.4 10.3 73.6 10.1 0.001
43 (17.5) 59 (24.1) 0.0001
68 (27.6) 72 (29.4) 0.150
108 (43.9) 126 (51.4) 0.0001
43 (17.5) 88 (35.9) 0.001
59 (24.0) 58 (23.7) 0.843
146 (59.3) 140 (57.1) 0.06
205 (83.3) 201 (82.0) 0.244
146 (59.3) 111 (45.3) 0.043
0.320
95 (38.6) 101 (41.2)
103 (41.9) 85 (34.7)
48 (19.5) 60 (24.5)
0.001
114 (46.3) 74 (30.2)
104 (42.3) 114 (46.5)
22 (8.9) 47 (19.2)
0 (0) 9 (3.7)
1,063.8 1,124.3 1,210.7 1,427.9 0.142
101.9 26.0 125.6 48.9 0.001
1,923.1 2,228.9 4,195.2 3,721.5 0.001
177 (72.0) 146 (59.6) 0.0001
llin; NTproBNP  N-terminal pro-B-type natriuretic peptide.
ifferent Patient Subgroups
P Levels in Different Patient Subgroups
p Value
Median NTproBNP
(fmol/ml) p Value
0.0001 5,929.3 vs. 839.0 0.0001
0.0001 3,932.9 vs. 839.0 0.0001
0.0001 788.7 vs. 1,632.6 0.0001
0.0001 844.4 vs. 1,332.3 0.03
0.0001 1,100.8 vs. 812.6 0.0001
0.001 668.6 vs. 2,415.9 0.001
NS 1,021.6 vs. 616.5 0.001
0.0001 1,583.4 vs. 631.0 0.0001roAD
ated
tile
0.1
0)
2)
7)
5)
8)
2)
3)
3)
1)
0)
0)
5)
2)
)
,152.9
8.2
,780.8
3)s in D
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1
0
2
1
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April 10, 2007:1525–32 Pro-Adrenomedullin in AMIine) were independent predictors of death or heart failure
Table 3).
The Kaplan-Meier survival curve showed a significantly
etter clinical outcome in patients with MR-proADM
elow the median (0.73 nmol/l) compared with those with
R-proADM above the median (log rank chi-square test
1.27, p  0.0001) (Fig. 3). This was also true for
TproBNP (log rank chi-square test 68.27, p  0.0001)
Fig. 4). In patients stratified by NTproBNP (median 914
mol/l), MR-proADM gave additional information on
eath and heart failure in those patients who had NT-
roBNP levels above the median (log rank chi-square test
or linear trend of factor levels, pooled over NTproBNP
trata, 49.07, p  0.0001) (Fig. 5), and even for patients
elow the NTproBNP median value, MR-proADM had
ome predictive value (log rank chi-square test 5.12, p 
.024) (Fig. 5). Patients in the top quartile for MR-
roADM (above 1.04 nmol/l) had a significantly higher
ortality than those in quartiles 1 to 3 (p  0.0001 for all).
or NTproBNP below the median, those patients in the top
uartile of MR-proADM had higher event rates than those
n quartile 1 (p 0.006) and quartile 2 (p 0.018) (Fig. 5).
The event rates at 1 year for both death and heart failure
eadmission or death alone in patients stratified by median
TproBNP (914 pmol/l) and quartiles of MR-proADM
re shown in Figure 6, in which the top quartile of
R-proADM (1.04 nmol/l) predicted those at highest risk.
Figure 2 Combined ROC Curve
Receiver-operating characteristic (ROC) curve comparing N-terminal pro-B-type
natriuretic peptide (NTproBNP), midregional pro-adrenomedullin (MR-proADM),
and the combined predicted probabilities from a binary logistic model for pre-
diction of death or heart failure.econdary end points: MR-proADM and NTproBNP as
redictors of death or heart failure as individual end
oints. On Cox proportional hazards modeling, the stron-
est independent predictors of death were MR-proADM
hazard ratio [HR] 4.86, p  0.001) and NTproBNP (HR
.64, p  0.0001), the other independent predictors were
ge (HR 1.06, p  0.0001) and history of AMI (HR 1.64,
 0.019). Such modeling on heart failure readmissions
ielded the following independent predictors: MR-
roADM (HR 7.29, p  0.0001), NTproBNP (HR 1.71,
 0.034), Killip class 1 (HR 2.04, p  0.014), and
istory of AMI (HR 1.93, p  0.011). Kaplan-Meier
nalysis on death or heart failure as individual end points
howed a significantly better clinical outcome in patients
ith MR-proADM below the median compared with those
ith MR-proADM above the median (log rank chi-square
est 42.4 and 28.65 respectively, p  0.0001). In addition,
Figure 3 Kaplan-Meier Curve: MR-proADM
Time to death or heart failure related to
plasma midregional pro-adrenomedullin (MR-proADM).
ultivariate Cox Proportional Hazards Regressionodel of Significant Predictors of Death oreart Failure
Table 3
Multivariate Cox Proportional Hazards Regression
Model of Significant Predictors of Death or
Heart Failure
Variable Hazard Ratio 95% Confidence Interval p Value
Log MR-proADM 3.63 1.48–8.90 0.005
Log NTproBNP 2.67 1.82–3.90 0.0001
Age 1.03 1.02–1.05 0.0001
Gender 0.69 0.46–0.96 0.031
History of AMI 1.76 1.24–2.50 0.001
Log creatinine 4.05 0.99–16.67 0.052
bbreviations as in Table 1.
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Pro-Adrenomedullin in AMI April 10, 2007:1525–32uartiles of MR-proADM predicted those with the highest
ortality or readmission with heart failure, stratified by
TproBNP levels above the median (log rank chi-square
est for linear trend of factor levels, pooled over NTproBNP
trata, 34.61 and 21.1, respectively, p  0.0001).
iscussion
his is the first report investigating the prognostic potential
fter AMI of MR-proADM in a large cohort of patients
rom a single center. Moreover, we compared this with
TproBNP, a well-established marker of death and heart
ailure after AMI. Our data indicate by survival analysis
sing both Kaplan-Meier and Cox proportional hazard
odels that MR-proADM is a powerful independent pre-
ictor of death and heart failure, with combined levels of
R-proADM and NTproBNP giving additive prognostic
nformation.
Reperfusion therapy and the application of secondary pre-
ention therapies have improved survival after AMI. Despite
his, outcome remains poor for some patients (23). A multi-
arker strategy for outcome after AMI using independent
iomarkers may provide complementary information through
ntegrating the different mechanistic pathways involved (24).
ur data indicate that although MR-proADM and NT-
roBNP individually have similar prognostic utility, the 2 mark-
rs considered together provide complementary information.
Multivariate analyses (binary and the more statistically
owerful Cox regression) showed that both MR-proADM
Figure 4 Kaplan-Meier Curve: NTproBNP
Time to death or heart failure related to
plasma N-terminal pro-B-type natriuretic peptide (NTproBNP).nd NTproBNP retained statistically significant power forrediction of death and heart failure independent of other
emographic and clinical variables. However, the combina-
ion of MR-proADM and NTproBNP in a multimarker
isk stratification approach generated an increased area
nder the receiver-operating characteristic curve and greater
redictive accuracy. Importantly, Kaplan-Meier analysis
howed that MR-proADM was particularly useful in the
roup of patients in whom NTproBNP was elevated, in
articular those with levels above the top quartile (1.04 nmol/l).
ur data indicate that patients can be risk-stratified more
recisely than is possible using NTproBNP alone.
The complementary prognostic utility of these peptides
ay suggest that there are differences in their pathophysi-
logical roles, or in the stimuli to their release. However
here are some common associations, suggesting some
imilarities in the stimuli leading to the secretion of MR-
Figure 5 Kaplan-Meier Curve: MR-proADM
Quartiles Stratified by NTproBNP
Quartiles of MR-proADM are shown predicting the primary end point of death or
heart failure in patients stratified by NTproBNP less than or greater than the
median. Abbreviations as in Figure 2.
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April 10, 2007:1525–32 Pro-Adrenomedullin in AMIroADM and NTproBNP; both levels increase with age
nd both show higher levels in women. The NTproBNP is
more stable byproduct in the production of BNP (25). In
similar fashion, MR-proADM is the more stable byprod-
ct of ADM released in a 1:1 ratio. The current findings
onfirm that the ADM system may be another candidate
eurohormonal pathway, in addition to the renin-
ngiotensin and sympathetic nervous systems that may be
ssociated with a poor outcome after AMI.
In a previous study, ADM was found to be weakly
redictive of death during follow-up after AMI (1). How-
Figure 6 Three-Dimensional Bar Chart
Annual event rates for death and for death or heart failure in patients stratified
by NTproBNP less than or greater than the median and by MR-proADM quar-
tiles. Abbreviations as in Figure 2.ver, its independent predictive power was lost for death and
deart failure when NTproBNP was evaluated. Interestingly,
DM was not increased in patients who later died or
eveloped heart failure (1). In another study, ADM was
ound to be an independent predictor of death and cardio-
enic shock after AMI (18). Adrenomedullin has also been
hown to be increased in heart failure (17,26), with levels
ncreasing with the severity of New York Heart Association
unctional class (16). The apparent discrepancy between our
tudy and the previous investigation (1) may relate to the
ize of populations investigated. However, the confirmation
f the independent predictive value of MR-proADM to-
ether with NTproBNP may have been achieved because of
he improved design of the MR-proADM assay, which
easures prohormone that does not associate with binding
roteins or receptors, resulting in a short half-life (11). The
enefit of measuring the prohormones over the active
eptide is that the lack of receptor binding or protein
nteractions and the longer half-lives result in higher easily
easurable plasma levels.
Adrenomedullin may have a number of advantageous
ffects in the post-AMI period, causing vasodilation (with
eduction of arterial and cardiac filling pressures) at a time
hen the myocardium has been compromised and may
ause increased myocardial contractility via its downstream
ctions on cAMP (6). Adrenomedullin may also play a role
n maintaining sodium balance, inhibiting the production of
ldosterone despite an elevated renin activity, thereby opti-
izing cardiac filling at a time when the ventricle has taken
n insult (27).
tudy limitations. This was a single-center study, and the
esults need to be replicated in larger multicenter studies.
here was a preponderance of ST-segment elevation AMI,
ecause cut points for non–ST-segment elevation AMI may
eed to be independently established. Our study used blood
amples in the recovery phase of AMI, and the utility of
nitial triage blood samples should be investigated.
onclusions
his report confirms activation of the ADM system after
MI and MR-proADM to be a powerful new prognostic
arker of death or heart failure and the combined end
oint of both outcomes, in patients with AMI, indepen-
ent of established conventional risk factors and newer
lasma biomarkers such as NTproBNP. A multimarker
pproach with MR-proADM and NTproBNP is more
nformative than either marker alone and may be useful
or risk stratification in AMI patients, with the possibility
f changes in the investigation and therapy of such
ndividuals.
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